Story perspectives

Lilly and Novo Battle for Diabetes Drug Dominance

8/30/2025

34 6

Summary

Story summary

Eli Lilly and Novo Nordisk are key competitors in the diabetes and obesity drug market, with market caps of $656 billion and $241 billion, respectively.
Lilly's tirzepatide generated $8.6 billion in Q2 2025, while Novo's semaglutide earned approximately $8 billion.
Analysts estimate Lilly's orforglipron could achieve $15–20 billion in annual sales; Novo's oral semaglutide may reach $25–30 billion.
U.S. drug pricing reforms may affect Lilly's margins, while Novo benefits from growth in international sales.

1 of 1

Story summary

Eli Lilly and Novo Nordisk are key competitors in the diabetes and obesity drug market, with market caps of $656 billion and $241 billion, respectively.
Lilly's tirzepatide generated $8.6 billion in Q2 2025, while Novo's semaglutide earned approximately $8 billion.
Analysts estimate Lilly's orforglipron could achieve $15–20 billion in annual sales; Novo's oral semaglutide may reach $25–30 billion.
U.S. drug pricing reforms may affect Lilly's margins, while Novo benefits from growth in international sales.